Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Has Big Plans To Become A Big Pharma In Coming Year

This article was originally published in The Pink Sheet Daily

Executive Summary

The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.

You may also be interested in...



Is Valeant The Fix to Salix Inventory Woes?

The Canadian pharma is willing to bet $14.5 billion that it can take care of the specialty pharma’s stocking level issues and still pull in $500 million in synergies with in the first six months.

Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel